#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Cutaneous squamous cell carcinoma ( cSCC ) is the second most common type of cancer with an annual incidence of over one million globally .
2-1	16-25	Cutaneous	object[3]	new[3]	appos	2-6[0_3]
2-2	26-34	squamous	object[3]	new[3]	_	_
2-3	35-39	cell	place|object[3]	new|new[3]	coref	5-7
2-4	40-49	carcinoma	object[3]	new[3]	_	_
2-5	50-51	(	_	_	_	_
2-6	52-56	cSCC	object	giv	coref	2-9[5_0]
2-7	57-58	)	_	_	_	_
2-8	59-61	is	_	_	_	_
2-9	62-65	the	object[5]	giv[5]	coref	3-31[0_5]
2-10	66-72	second	object[5]	giv[5]	_	_
2-11	73-77	most	object[5]	giv[5]	_	_
2-12	78-84	common	object[5]	giv[5]	_	_
2-13	85-89	type	object[5]	giv[5]	_	_
2-14	90-92	of	object[5]	giv[5]	_	_
2-15	93-99	cancer	object[5]|abstract	giv[5]|new	coref	8-17
2-16	100-104	with	object[5]	giv[5]	_	_
2-17	105-107	an	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-18	108-114	annual	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-19	115-124	incidence	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-20	125-127	of	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-21	128-132	over	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-22	133-136	one	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-23	137-144	million	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-24	145-153	globally	object[5]|abstract[7]	giv[5]|new[7]	_	_
2-25	154-155	.	_	_	_	_

#Text=Chronic ultraviolet ( UV ) exposure was suggested to be responsible for DNA damage of normal keratinocytes in the epidermis , which leads to the development of skin cancers including cSCC .
3-1	156-163	Chronic	abstract[8]	new[8]	appos	3-4[0_8]
3-2	164-175	ultraviolet	abstract[8]	new[8]	_	_
3-3	176-177	(	_	_	_	_
3-4	178-180	UV	abstract	giv	_	_
3-5	181-182	)	_	_	_	_
3-6	183-191	exposure	abstract	new	_	_
3-7	192-195	was	_	_	_	_
3-8	196-205	suggested	_	_	_	_
3-9	206-208	to	_	_	_	_
3-10	209-211	be	_	_	_	_
3-11	212-223	responsible	_	_	_	_
3-12	224-227	for	_	_	_	_
3-13	228-231	DNA	substance|abstract[12]	new|new[12]	_	_
3-14	232-238	damage	abstract[12]	new[12]	_	_
3-15	239-241	of	abstract[12]	new[12]	_	_
3-16	242-248	normal	abstract[12]|substance[13]	new[12]|new[13]	_	_
3-17	249-262	keratinocytes	abstract[12]|substance[13]	new[12]|new[13]	_	_
3-18	263-265	in	abstract[12]|substance[13]	new[12]|new[13]	_	_
3-19	266-269	the	abstract[12]|substance[13]|object[14]	new[12]|new[13]|new[14]	_	_
3-20	270-279	epidermis	abstract[12]|substance[13]|object[14]	new[12]|new[13]|new[14]	_	_
3-21	280-281	,	_	_	_	_
3-22	282-287	which	_	_	_	_
3-23	288-293	leads	_	_	_	_
3-24	294-296	to	_	_	_	_
3-25	297-300	the	event[15]	new[15]	_	_
3-26	301-312	development	event[15]	new[15]	_	_
3-27	313-315	of	event[15]	new[15]	_	_
3-28	316-320	skin	event[15]|object|abstract[17]	new[15]|new|new[17]	_	_
3-29	321-328	cancers	event[15]|abstract[17]	new[15]|new[17]	_	_
3-30	329-338	including	event[15]|abstract[17]	new[15]|new[17]	_	_
3-31	339-343	cSCC	event[15]|abstract[17]|abstract	new[15]|new[17]|giv	coref	19-20
3-32	344-345	.	_	_	_	_

#Text=However , the detailed underlying molecular mechanisms for this transition still need to be fully elucidated .
4-1	346-353	However	_	_	_	_
4-2	354-355	,	_	_	_	_
4-3	356-359	the	abstract[19]	new[19]	coref	8-3[50_19]
4-4	360-368	detailed	abstract[19]	new[19]	_	_
4-5	369-379	underlying	abstract[19]	new[19]	_	_
4-6	380-389	molecular	abstract[19]	new[19]	_	_
4-7	390-400	mechanisms	abstract[19]	new[19]	_	_
4-8	401-404	for	abstract[19]	new[19]	_	_
4-9	405-409	this	abstract[19]|event[20]	new[19]|new[20]	_	_
4-10	410-420	transition	abstract[19]|event[20]	new[19]|new[20]	_	_
4-11	421-426	still	_	_	_	_
4-12	427-431	need	_	_	_	_
4-13	432-434	to	_	_	_	_
4-14	435-437	be	_	_	_	_
4-15	438-443	fully	_	_	_	_
4-16	444-454	elucidated	_	_	_	_
4-17	455-456	.	_	_	_	_

#Text=Apoptosis is one type of programmed cell death , which is initiated by intrinsic or extrinsic signals and finely-tuned by many factors including BCL-2 family proteins .
5-1	457-466	Apoptosis	abstract	new	coref	5-3[22_0]
5-2	467-469	is	_	_	_	_
5-3	470-473	one	abstract[22]	giv[22]	coref	6-24[0_22]
5-4	474-478	type	abstract[22]	giv[22]	_	_
5-5	479-481	of	abstract[22]	giv[22]	_	_
5-6	482-492	programmed	abstract[22]|event[24]	giv[22]|new[24]	coref	7-3[39_24]
5-7	493-497	cell	abstract[22]|place|event[24]	giv[22]|giv|new[24]	coref	7-3
5-8	498-503	death	abstract[22]|event[24]	giv[22]|new[24]	_	_
5-9	504-505	,	_	_	_	_
5-10	506-511	which	_	_	_	_
5-11	512-514	is	_	_	_	_
5-12	515-524	initiated	_	_	_	_
5-13	525-527	by	_	_	_	_
5-14	528-537	intrinsic	abstract[25]	new[25]	_	_
5-15	538-540	or	abstract[25]	new[25]	_	_
5-16	541-550	extrinsic	abstract[25]	new[25]	_	_
5-17	551-558	signals	abstract[25]	new[25]	_	_
5-18	559-562	and	_	_	_	_
5-19	563-575	finely-tuned	_	_	_	_
5-20	576-578	by	_	_	_	_
5-21	579-583	many	abstract[26]	new[26]	coref	17-4[136_26]
5-22	584-591	factors	abstract[26]	new[26]	_	_
5-23	592-601	including	abstract[26]	new[26]	_	_
5-24	602-607	BCL-2	abstract[26]|substance[28]	new[26]|new[28]	coref	6-6[33_28]
5-25	608-614	family	abstract[26]|organization|substance[28]	new[26]|new|new[28]	coref	6-2
5-26	615-623	proteins	abstract[26]|substance[28]	new[26]|new[28]	_	_
5-27	624-625	.	_	_	_	_

#Text=BCL-2 family members , including both anti-apoptotic and pro-apoptotic BCL-2 family proteins , govern mitochondrial outer membrane permeabilization ( MOMP ) to regulate apoptosis .
6-1	626-631	BCL-2	person[30]	new[30]	coref	9-1[55_30]
6-2	632-638	family	organization|person[30]	giv|new[30]	coref	6-11
6-3	639-646	members	person[30]	new[30]	_	_
6-4	647-648	,	person[30]	new[30]	_	_
6-5	649-658	including	person[30]	new[30]	_	_
6-6	659-663	both	person[30]|substance[33]	new[30]|giv[33]	coref	13-10[97_33]
6-7	664-678	anti-apoptotic	person[30]|substance[33]	new[30]|giv[33]	_	_
6-8	679-682	and	person[30]|substance[33]	new[30]|giv[33]	_	_
6-9	683-696	pro-apoptotic	person[30]|substance[33]	new[30]|giv[33]	_	_
6-10	697-702	BCL-2	person[30]|abstract|substance[33]	new[30]|new|giv[33]	coref	9-4
6-11	703-709	family	person[30]|organization|substance[33]	new[30]|giv|giv[33]	coref	9-49[73_0]
6-12	710-718	proteins	person[30]|substance[33]	new[30]|giv[33]	_	_
6-13	719-720	,	_	_	_	_
6-14	721-727	govern	_	_	_	_
6-15	728-741	mitochondrial	_	_	_	_
6-16	742-747	outer	abstract[35]	new[35]	appos	6-20[0_35]
6-17	748-756	membrane	object|abstract[35]	new|new[35]	coref	16-34
6-18	757-773	permeabilization	abstract[35]	new[35]	_	_
6-19	774-775	(	_	_	_	_
6-20	776-780	MOMP	abstract	giv	coref	7-8
6-21	781-782	)	_	_	_	_
6-22	783-785	to	_	_	_	_
6-23	786-794	regulate	_	_	_	_
6-24	795-804	apoptosis	event	giv	coref	8-7
6-25	805-806	.	_	_	_	_

#Text=When apoptotic cell death program starts , MOMP releases cytochrome c to cytosol and activates caspase-family proteases for initiating apoptotic events .
7-1	807-811	When	_	_	_	_
7-2	812-821	apoptotic	event[40]	new[40]	_	_
7-3	822-826	cell	place|event[39]|event[40]	giv|giv[39]|new[40]	coref|coref	10-20[0_39]|14-11
7-4	827-832	death	event[39]|event[40]	giv[39]|new[40]	_	_
7-5	833-840	program	event[40]	new[40]	_	_
7-6	841-847	starts	_	_	_	_
7-7	848-849	,	_	_	_	_
7-8	850-854	MOMP	event|event[42]|abstract[43]	giv|new[42]|new[43]	_	_
7-9	855-863	releases	event[42]|abstract[43]	new[42]|new[43]	_	_
7-10	864-874	cytochrome	abstract[43]	new[43]	_	_
7-11	875-876	c	abstract[43]|substance	new[43]|new	_	_
7-12	877-879	to	abstract[43]	new[43]	_	_
7-13	880-887	cytosol	abstract[43]|place	new[43]|new	_	_
7-14	888-891	and	_	_	_	_
7-15	892-901	activates	_	_	_	_
7-16	902-916	caspase-family	_	_	_	_
7-17	917-926	proteases	abstract	new	_	_
7-18	927-930	for	_	_	_	_
7-19	931-941	initiating	_	_	_	_
7-20	942-951	apoptotic	substance|event[48]	new|new[48]	_	_
7-21	952-958	events	event[48]	new[48]	_	_
7-22	959-960	.	_	_	_	_

#Text=Tumors develop effective mechanisms to resist apoptosis and thus become one of the hallmark features of cancer .
8-1	961-967	Tumors	object	new	coref	19-20[155_0]
8-2	968-975	develop	_	_	_	_
8-3	976-985	effective	abstract[50]	giv[50]	coref	21-3[164_50]
8-4	986-996	mechanisms	abstract[50]	giv[50]	_	_
8-5	997-999	to	_	_	_	_
8-6	1000-1006	resist	_	_	_	_
8-7	1007-1016	apoptosis	abstract	giv	coref	20-14[162_0]
8-8	1017-1020	and	_	_	_	_
8-9	1021-1025	thus	_	_	_	_
8-10	1026-1032	become	_	_	_	_
8-11	1033-1036	one	abstract[52]	new[52]	_	_
8-12	1037-1039	of	abstract[52]	new[52]	_	_
8-13	1040-1043	the	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-14	1044-1052	hallmark	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-15	1053-1061	features	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-16	1062-1064	of	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-17	1065-1071	cancer	abstract[52]|abstract[53]|abstract	new[52]|new[53]|giv	coref	10-17
8-18	1072-1073	.	_	_	_	_

#Text=The lead member BCL-2 and its homologue BCL-XL ( BCL2L1 ) are featured by the presence of four conserved BH domains , three of which , BH1 , BH2 , and BH3 domains , are responsible for their antiapoptotic role mainly by interactions with other proapoptotic members of the BCL-2 family .
9-1	1074-1077	The	person[55]	giv[55]	ana	9-38[0_55]
9-2	1078-1082	lead	person[55]	giv[55]	_	_
9-3	1083-1089	member	person[55]	giv[55]	_	_
9-4	1090-1095	BCL-2	object	giv	ana	9-6
9-5	1096-1099	and	_	_	_	_
9-6	1100-1103	its	object|object[58]	giv|new[58]	coref	23-6[0_58]
9-7	1104-1113	homologue	object[58]	new[58]	_	_
9-8	1114-1120	BCL-XL	object[58]	new[58]	_	_
9-9	1121-1122	(	_	_	_	_
9-10	1123-1129	BCL2L1	abstract	new	_	_
9-11	1130-1131	)	_	_	_	_
9-12	1132-1135	are	_	_	_	_
9-13	1136-1144	featured	_	_	_	_
9-14	1145-1147	by	_	_	_	_
9-15	1148-1151	the	abstract[60]	new[60]	_	_
9-16	1152-1160	presence	abstract[60]	new[60]	_	_
9-17	1161-1163	of	abstract[60]	new[60]	_	_
9-18	1164-1168	four	abstract[60]|abstract[62]	new[60]|new[62]	_	_
9-19	1169-1178	conserved	abstract[60]|abstract[62]	new[60]|new[62]	_	_
9-20	1179-1181	BH	abstract[60]|person|abstract[62]	new[60]|new|new[62]	_	_
9-21	1182-1189	domains	abstract[60]|abstract[62]	new[60]|new[62]	_	_
9-22	1190-1191	,	abstract[60]	new[60]	_	_
9-23	1192-1197	three	abstract[60]|quantity	new[60]|new	_	_
9-24	1198-1200	of	abstract[60]	new[60]	_	_
9-25	1201-1206	which	abstract[60]|abstract[64]	new[60]|new[64]	_	_
9-26	1207-1208	,	abstract[60]|abstract[64]	new[60]|new[64]	_	_
9-27	1209-1212	BH1	abstract[60]|abstract[64]	new[60]|new[64]	_	_
9-28	1213-1214	,	abstract[60]	new[60]	_	_
9-29	1215-1218	BH2	abstract[60]|abstract	new[60]|new	_	_
9-30	1219-1220	,	abstract[60]	new[60]	_	_
9-31	1221-1224	and	abstract[60]	new[60]	_	_
9-32	1225-1228	BH3	abstract[60]|person|abstract[67]	new[60]|new|new[67]	_	_
9-33	1229-1236	domains	abstract[60]|abstract[67]	new[60]|new[67]	_	_
9-34	1237-1238	,	_	_	_	_
9-35	1239-1242	are	_	_	_	_
9-36	1243-1254	responsible	_	_	_	_
9-37	1255-1258	for	_	_	_	_
9-38	1259-1264	their	person|abstract[69]	giv|new[69]	coref	9-45[71_0]
9-39	1265-1278	antiapoptotic	abstract[69]	new[69]	_	_
9-40	1279-1283	role	abstract[69]	new[69]	_	_
9-41	1284-1290	mainly	_	_	_	_
9-42	1291-1293	by	_	_	_	_
9-43	1294-1306	interactions	abstract[70]	new[70]	_	_
9-44	1307-1311	with	abstract[70]	new[70]	_	_
9-45	1312-1317	other	abstract[70]|person[71]	new[70]|giv[71]	coref	10-5[76_71]
9-46	1318-1330	proapoptotic	abstract[70]|person[71]	new[70]|giv[71]	_	_
9-47	1331-1338	members	abstract[70]|person[71]	new[70]|giv[71]	_	_
9-48	1339-1341	of	abstract[70]|person[71]	new[70]|giv[71]	_	_
9-49	1342-1345	the	abstract[70]|person[71]|organization[73]	new[70]|giv[71]|giv[73]	coref	12-10[0_73]
9-50	1346-1351	BCL-2	abstract[70]|person[71]|person|organization[73]	new[70]|giv[71]|new|giv[73]	coref	10-6
9-51	1352-1358	family	abstract[70]|person[71]|organization[73]	new[70]|giv[71]|giv[73]	_	_
9-52	1359-1360	.	_	_	_	_

#Text=Inhibiting the activities of anti-apoptotic BCL-2 members by drugs or neutralizing by BH3 peptides to prime cancer cells to death has been regarded as effective therapeutic modalities .
10-1	1361-1371	Inhibiting	_	_	_	_
10-2	1372-1375	the	abstract[74]	new[74]	_	_
10-3	1376-1386	activities	abstract[74]	new[74]	_	_
10-4	1387-1389	of	abstract[74]	new[74]	_	_
10-5	1390-1404	anti-apoptotic	abstract[74]|person[76]	new[74]|giv[76]	coref	11-13[87_76]
10-6	1405-1410	BCL-2	abstract[74]|event|person[76]	new[74]|giv|giv[76]	coref	11-14
10-7	1411-1418	members	abstract[74]|person[76]	new[74]|giv[76]	_	_
10-8	1419-1421	by	abstract[74]|person[76]	new[74]|giv[76]	_	_
10-9	1422-1427	drugs	abstract[74]|person[76]|substance	new[74]|giv[76]|new	_	_
10-10	1428-1430	or	abstract[74]|person[76]	new[74]|giv[76]	_	_
10-11	1431-1443	neutralizing	abstract[74]|person[76]	new[74]|giv[76]	_	_
10-12	1444-1446	by	_	_	_	_
10-13	1447-1450	BH3	abstract|substance[79]	new|new[79]	coref	15-1[109_79]
10-14	1451-1459	peptides	substance[79]	new[79]	_	_
10-15	1460-1462	to	substance[79]	new[79]	_	_
10-16	1463-1468	prime	substance[79]|object[81]	new[79]|new[81]	coref	15-22[115_81]
10-17	1469-1475	cancer	substance[79]|abstract|object[81]	new[79]|giv|new[81]	coref	11-17
10-18	1476-1481	cells	substance[79]|object[81]	new[79]|new[81]	_	_
10-19	1482-1484	to	substance[79]|object[81]	new[79]|new[81]	_	_
10-20	1485-1490	death	substance[79]|object[81]|event	new[79]|new[81]|giv	coref	14-10[107_0]
10-21	1491-1494	has	_	_	_	_
10-22	1495-1499	been	_	_	_	_
10-23	1500-1508	regarded	_	_	_	_
10-24	1509-1511	as	_	_	_	_
10-25	1512-1521	effective	_	_	_	_
10-26	1522-1533	therapeutic	_	_	_	_
10-27	1534-1544	modalities	_	_	_	_
10-28	1545-1546	.	_	_	_	_

#Text=In another way , transcriptionally or post-transcriptionally repressing the expression levels of anti-apoptotic BCL-2 members in cancer is also promising .
11-1	1547-1549	In	_	_	_	_
11-2	1550-1557	another	abstract[83]	new[83]	_	_
11-3	1558-1561	way	abstract[83]	new[83]	_	_
11-4	1562-1563	,	_	_	_	_
11-5	1564-1581	transcriptionally	_	_	_	_
11-6	1582-1584	or	_	_	_	_
11-7	1585-1607	post-transcriptionally	_	_	_	_
11-8	1608-1618	repressing	_	_	_	_
11-9	1619-1622	the	abstract[85]	new[85]	_	_
11-10	1623-1633	expression	abstract|abstract[85]	new|new[85]	coref	12-6[90_0]
11-11	1634-1640	levels	abstract[85]	new[85]	_	_
11-12	1641-1643	of	abstract[85]	new[85]	_	_
11-13	1644-1658	anti-apoptotic	abstract[85]|person[87]	new[85]|giv[87]	coref	12-9[93_87]
11-14	1659-1664	BCL-2	abstract[85]|event|person[87]	new[85]|giv|giv[87]	coref	12-9
11-15	1665-1672	members	abstract[85]|person[87]	new[85]|giv[87]	_	_
11-16	1673-1675	in	abstract[85]|person[87]	new[85]|giv[87]	_	_
11-17	1676-1682	cancer	abstract[85]|person[87]|abstract	new[85]|giv[87]|giv	_	_
11-18	1683-1685	is	_	_	_	_
11-19	1686-1690	also	_	_	_	_
11-20	1691-1700	promising	_	_	_	_
11-21	1701-1702	.	_	_	_	_

#Text=However , the mechanism regulating the expression of BCL-2 family members still remain unclear .
12-1	1703-1710	However	_	_	_	_
12-2	1711-1712	,	_	_	_	_
12-3	1713-1716	the	abstract[89]	new[89]	_	_
12-4	1717-1726	mechanism	abstract[89]	new[89]	_	_
12-5	1727-1737	regulating	_	_	_	_
12-6	1738-1741	the	abstract[90]	giv[90]	_	_
12-7	1742-1752	expression	abstract[90]	giv[90]	_	_
12-8	1753-1755	of	abstract[90]	giv[90]	_	_
12-9	1756-1761	BCL-2	abstract[90]|event|person[93]	giv[90]|giv|giv[93]	_	_
12-10	1762-1768	family	abstract[90]|organization|person[93]	giv[90]|giv|giv[93]	_	_
12-11	1769-1776	members	abstract[90]|person[93]	giv[90]|giv[93]	_	_
12-12	1777-1782	still	_	_	_	_
12-13	1783-1789	remain	_	_	_	_
12-14	1790-1797	unclear	_	_	_	_
12-15	1798-1799	.	_	_	_	_

#Text=Autophagy is an evolutionarily-conserved catabolic process , during which “ useless ” proteins and damaged organelles are sequestrated into autophagosomes and fused with lysosomes to form autolysosomes for bulk degradation of embedded components .
13-1	1800-1809	Autophagy	abstract	new	coref	13-3[96_0]
13-2	1810-1812	is	_	_	_	_
13-3	1813-1815	an	abstract[96]	giv[96]	coref	14-2[105_96]
13-4	1816-1840	evolutionarily-conserved	abstract[96]	giv[96]	_	_
13-5	1841-1850	catabolic	person|abstract[96]	new|giv[96]	_	_
13-6	1851-1858	process	abstract[96]	giv[96]	_	_
13-7	1859-1860	,	_	_	_	_
13-8	1861-1867	during	_	_	_	_
13-9	1868-1873	which	_	_	_	_
13-10	1874-1875	“	substance[97]	giv[97]	_	_
13-11	1876-1883	useless	substance[97]	giv[97]	_	_
13-12	1884-1885	”	substance[97]	giv[97]	_	_
13-13	1886-1894	proteins	substance[97]	giv[97]	_	_
13-14	1895-1898	and	substance[97]	giv[97]	_	_
13-15	1899-1906	damaged	substance[97]|object[98]	giv[97]|new[98]	_	_
13-16	1907-1917	organelles	substance[97]|object[98]	giv[97]|new[98]	_	_
13-17	1918-1921	are	_	_	_	_
13-18	1922-1934	sequestrated	_	_	_	_
13-19	1935-1939	into	_	_	_	_
13-20	1940-1954	autophagosomes	object	new	_	_
13-21	1955-1958	and	_	_	_	_
13-22	1959-1964	fused	_	_	_	_
13-23	1965-1969	with	_	_	_	_
13-24	1970-1979	lysosomes	object	new	_	_
13-25	1980-1982	to	_	_	_	_
13-26	1983-1987	form	_	_	_	_
13-27	1988-2001	autolysosomes	place	new	_	_
13-28	2002-2005	for	_	_	_	_
13-29	2006-2010	bulk	abstract[102]	new[102]	coref	16-41[134_102]
13-30	2011-2022	degradation	abstract[102]	new[102]	_	_
13-31	2023-2025	of	abstract[102]	new[102]	_	_
13-32	2026-2034	embedded	abstract[102]|abstract[103]	new[102]|new[103]	coref	16-43[0_103]
13-33	2035-2045	components	abstract[102]|abstract[103]	new[102]|new[103]	_	_
13-34	2046-2047	.	_	_	_	_

#Text=Except the dysregulated autophagic process defined as type II programmed cell death , autophagy is generally regarded as protective cellular process .
14-1	2048-2054	Except	_	_	_	_
14-2	2055-2058	the	abstract[105]	giv[105]	coref	14-14[0_105]
14-3	2059-2071	dysregulated	abstract[105]	giv[105]	_	_
14-4	2072-2082	autophagic	abstract|abstract[105]	new|giv[105]	_	_
14-5	2083-2090	process	abstract[105]	giv[105]	_	_
14-6	2091-2098	defined	_	_	_	_
14-7	2099-2101	as	_	_	_	_
14-8	2102-2106	type	_	_	_	_
14-9	2107-2109	II	_	_	_	_
14-10	2110-2120	programmed	event[107]	giv[107]	_	_
14-11	2121-2125	cell	place|event[107]	giv|giv[107]	_	_
14-12	2126-2131	death	event[107]	giv[107]	_	_
14-13	2132-2133	,	_	_	_	_
14-14	2134-2143	autophagy	event	giv	coref	16-26
14-15	2144-2146	is	_	_	_	_
14-16	2147-2156	generally	_	_	_	_
14-17	2157-2165	regarded	_	_	_	_
14-18	2166-2168	as	_	_	_	_
14-19	2169-2179	protective	_	_	_	_
14-20	2180-2188	cellular	_	_	_	_
14-21	2189-2196	process	_	_	_	_
14-22	2197-2198	.	_	_	_	_

#Text=The recycled peptides , nucleotides and lipids together with the energy are critical to the maintenance of cellular homeostasis and support tumor cells to survive under stressful environment .
15-1	2199-2202	The	substance[109]	giv[109]	_	_
15-2	2203-2211	recycled	substance[109]	giv[109]	_	_
15-3	2212-2220	peptides	substance[109]	giv[109]	_	_
15-4	2221-2222	,	substance[109]	giv[109]	_	_
15-5	2223-2234	nucleotides	substance[109]|plant	giv[109]|new	_	_
15-6	2235-2238	and	substance[109]	giv[109]	_	_
15-7	2239-2245	lipids	substance[109]|substance[111]	giv[109]|new[111]	_	_
15-8	2246-2254	together	substance[109]|substance[111]|substance[112]	giv[109]|new[111]|new[112]	_	_
15-9	2255-2259	with	substance[109]|substance[111]|substance[112]	giv[109]|new[111]|new[112]	_	_
15-10	2260-2263	the	substance[109]|substance[111]|substance[112]	giv[109]|new[111]|new[112]	_	_
15-11	2264-2270	energy	substance[109]|substance[111]|substance[112]	giv[109]|new[111]|new[112]	_	_
15-12	2271-2274	are	_	_	_	_
15-13	2275-2283	critical	_	_	_	_
15-14	2284-2286	to	_	_	_	_
15-15	2287-2290	the	event[113]	new[113]	_	_
15-16	2291-2302	maintenance	event[113]	new[113]	_	_
15-17	2303-2305	of	event[113]	new[113]	_	_
15-18	2306-2314	cellular	event[113]|abstract[114]	new[113]|new[114]	_	_
15-19	2315-2326	homeostasis	event[113]|abstract[114]	new[113]|new[114]	_	_
15-20	2327-2330	and	_	_	_	_
15-21	2331-2338	support	_	_	_	_
15-22	2339-2344	tumor	object[115]	giv[115]	coref	19-23[0_115]
15-23	2345-2350	cells	object[115]	giv[115]	_	_
15-24	2351-2353	to	_	_	_	_
15-25	2354-2361	survive	_	_	_	_
15-26	2362-2367	under	_	_	_	_
15-27	2368-2377	stressful	abstract[116]	new[116]	_	_
15-28	2378-2389	environment	abstract[116]	new[116]	_	_
15-29	2390-2391	.	_	_	_	_

#Text=Autophagy-related genes ( ATGs ) , including ULK1 ( ATG1 ) , ATG3 , and ATG12 etc. , are involved in the distinct stages of autophagy : initiation , autophagosome nucleation , autophagosome membrane expansion , fusion with lysosome and the intravesicular components degradation .
16-1	2392-2409	Autophagy-related	abstract[117]	new[117]	appos	16-4[0_117]
16-2	2410-2415	genes	abstract[117]	new[117]	_	_
16-3	2416-2417	(	_	_	_	_
16-4	2418-2422	ATGs	abstract	giv	coref	17-10[138_0]
16-5	2423-2424	)	_	_	_	_
16-6	2425-2426	,	_	_	_	_
16-7	2427-2436	including	_	_	_	_
16-8	2437-2441	ULK1	abstract	new	appos	16-10
16-9	2442-2443	(	_	_	_	_
16-10	2444-2448	ATG1	abstract	giv	coref	23-14
16-11	2449-2450	)	_	_	_	_
16-12	2451-2452	,	_	_	_	_
16-13	2453-2457	ATG3	abstract	new	coref	23-16
16-14	2458-2459	,	_	_	_	_
16-15	2460-2463	and	_	_	_	_
16-16	2464-2469	ATG12	object	new	coref	23-19
16-17	2470-2474	etc.	_	_	_	_
16-18	2475-2476	,	_	_	_	_
16-19	2477-2480	are	_	_	_	_
16-20	2481-2489	involved	_	_	_	_
16-21	2490-2492	in	_	_	_	_
16-22	2493-2496	the	abstract[123]	new[123]	_	_
16-23	2497-2505	distinct	abstract[123]	new[123]	_	_
16-24	2506-2512	stages	abstract[123]	new[123]	_	_
16-25	2513-2515	of	abstract[123]	new[123]	_	_
16-26	2516-2525	autophagy	abstract[123]|event	new[123]|giv	coref	23-23
16-27	2526-2527	:	abstract[123]	new[123]	_	_
16-28	2528-2538	initiation	abstract[123]|event	new[123]|new	_	_
16-29	2539-2540	,	abstract[123]	new[123]	_	_
16-30	2541-2554	autophagosome	abstract[123]|abstract|event[127]	new[123]|new|new[127]	coref	16-33
16-31	2555-2565	nucleation	abstract[123]|event[127]	new[123]|new[127]	_	_
16-32	2566-2567	,	abstract[123]	new[123]	_	_
16-33	2568-2581	autophagosome	abstract[123]|abstract|event[130]	new[123]|giv|new[130]	_	_
16-34	2582-2590	membrane	abstract[123]|object|event[130]	new[123]|giv|new[130]	_	_
16-35	2591-2600	expansion	abstract[123]|event[130]	new[123]|new[130]	_	_
16-36	2601-2602	,	abstract[123]	new[123]	_	_
16-37	2603-2609	fusion	abstract[123]|event[131]	new[123]|new[131]	_	_
16-38	2610-2614	with	abstract[123]|event[131]	new[123]|new[131]	_	_
16-39	2615-2623	lysosome	abstract[123]|event[131]|object	new[123]|new[131]|new	_	_
16-40	2624-2627	and	abstract[123]	new[123]	_	_
16-41	2628-2631	the	abstract[123]|abstract[134]	new[123]|giv[134]	_	_
16-42	2632-2646	intravesicular	abstract[123]|abstract[134]	new[123]|giv[134]	_	_
16-43	2647-2657	components	abstract[123]|abstract|abstract[134]	new[123]|giv|giv[134]	_	_
16-44	2658-2669	degradation	abstract[123]|abstract[134]	new[123]|giv[134]	_	_
16-45	2670-2671	.	_	_	_	_

#Text=Signaling pathways or critical factors are involved in regulating ATG genes , including Class III PI3-kinase complex I , mTORC I complex , mTORC II complex and Beclin1 et al. .
17-1	2672-2681	Signaling	_	_	_	_
17-2	2682-2690	pathways	place	new	_	_
17-3	2691-2693	or	_	_	_	_
17-4	2694-2702	critical	abstract[136]	giv[136]	_	_
17-5	2703-2710	factors	abstract[136]	giv[136]	_	_
17-6	2711-2714	are	_	_	_	_
17-7	2715-2723	involved	_	_	_	_
17-8	2724-2726	in	_	_	_	_
17-9	2727-2737	regulating	_	_	_	_
17-10	2738-2741	ATG	abstract|abstract[138]	new|giv[138]	coref|coref	18-8|18-7[147_138]
17-11	2742-2747	genes	abstract[138]	giv[138]	_	_
17-12	2748-2749	,	abstract[138]	giv[138]	_	_
17-13	2750-2759	including	abstract[138]	giv[138]	_	_
17-14	2760-2765	Class	abstract[138]|abstract[139]	giv[138]|new[139]	_	_
17-15	2766-2769	III	abstract[138]|abstract[139]	giv[138]|new[139]	_	_
17-16	2770-2780	PI3-kinase	abstract[138]|abstract[139]|abstract	giv[138]|new[139]|new	_	_
17-17	2781-2788	complex	abstract[138]|abstract[139]	giv[138]|new[139]	_	_
17-18	2789-2790	I	abstract[138]|person	giv[138]|acc	_	_
17-19	2791-2792	,	abstract[138]	giv[138]	_	_
17-20	2793-2798	mTORC	abstract[138]|abstract	giv[138]|new	coref	17-24[144_0]
17-21	2799-2800	I	person	acc	_	_
17-22	2801-2808	complex	_	_	_	_
17-23	2809-2810	,	_	_	_	_
17-24	2811-2816	mTORC	abstract[144]	giv[144]	_	_
17-25	2817-2819	II	abstract[144]	giv[144]	_	_
17-26	2820-2827	complex	abstract[144]	giv[144]	_	_
17-27	2828-2831	and	abstract[144]	giv[144]	_	_
17-28	2832-2839	Beclin1	abstract[144]	giv[144]	_	_
17-29	2840-2842	et	abstract[144]	giv[144]	_	_
17-30	2843-2846	al.	abstract[144]	giv[144]	_	_
17-31	2847-2848	.	_	_	_	_

#Text=However , the transcriptional regulation of the ATG genes is not fully explored .
18-1	2849-2856	However	_	_	_	_
18-2	2857-2858	,	_	_	_	_
18-3	2859-2862	the	abstract[145]	new[145]	_	_
18-4	2863-2878	transcriptional	abstract[145]	new[145]	_	_
18-5	2879-2889	regulation	abstract[145]	new[145]	_	_
18-6	2890-2892	of	abstract[145]	new[145]	_	_
18-7	2893-2896	the	abstract[145]|abstract[147]	new[145]|giv[147]	coref	23-11[180_147]
18-8	2897-2900	ATG	abstract[145]|abstract|abstract[147]	new[145]|giv|giv[147]	coref	23-11
18-9	2901-2906	genes	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
18-10	2907-2909	is	_	_	_	_
18-11	2910-2913	not	_	_	_	_
18-12	2914-2919	fully	_	_	_	_
18-13	2920-2928	explored	_	_	_	_
18-14	2929-2930	.	_	_	_	_

#Text=In our previous study , Homeobox A9 ( HOXA9 ) was significantly downregulated and identified as tumor suppressor in cSCC tumors and cells .
19-1	2931-2933	In	_	_	_	_
19-2	2934-2937	our	person|abstract[149]	acc|new[149]	coref|ana	22-2[167_149]|22-5
19-3	2938-2946	previous	abstract[149]	new[149]	_	_
19-4	2947-2952	study	abstract[149]	new[149]	_	_
19-5	2953-2954	,	_	_	_	_
19-6	2955-2963	Homeobox	place|abstract[151]	new|new[151]	appos	19-9[0_151]
19-7	2964-2966	A9	abstract[151]	new[151]	_	_
19-8	2967-2968	(	_	_	_	_
19-9	2969-2974	HOXA9	abstract	giv	coref	20-1
19-10	2975-2976	)	_	_	_	_
19-11	2977-2980	was	_	_	_	_
19-12	2981-2994	significantly	_	_	_	_
19-13	2995-3008	downregulated	_	_	_	_
19-14	3009-3012	and	_	_	_	_
19-15	3013-3023	identified	_	_	_	_
19-16	3024-3026	as	_	_	_	_
19-17	3027-3032	tumor	abstract	new	coref	24-15
19-18	3033-3043	suppressor	_	_	_	_
19-19	3044-3046	in	_	_	_	_
19-20	3047-3051	cSCC	place|object[155]	giv|giv[155]	coref	23-2
19-21	3052-3058	tumors	object[155]	giv[155]	_	_
19-22	3059-3062	and	object[155]	giv[155]	_	_
19-23	3063-3068	cells	object[155]|object	giv[155]|giv	coref	20-16[163_0]
19-24	3069-3070	.	_	_	_	_

#Text=HOXA9 functions in repressing the proliferation , migration and invasiveness , while promoting apoptosis of cSCC cells .
20-1	3071-3076	HOXA9	abstract|abstract[158]	giv|new[158]	coref	21-7
20-2	3077-3086	functions	abstract[158]	new[158]	_	_
20-3	3087-3089	in	_	_	_	_
20-4	3090-3100	repressing	_	_	_	_
20-5	3101-3104	the	event[159]	new[159]	_	_
20-6	3105-3118	proliferation	event[159]	new[159]	_	_
20-7	3119-3120	,	_	_	_	_
20-8	3121-3130	migration	abstract	new	_	_
20-9	3131-3134	and	_	_	_	_
20-10	3135-3147	invasiveness	event	new	_	_
20-11	3148-3149	,	_	_	_	_
20-12	3150-3155	while	_	_	_	_
20-13	3156-3165	promoting	_	_	_	_
20-14	3166-3175	apoptosis	event[162]	giv[162]	coref	21-9[0_162]
20-15	3176-3178	of	event[162]	giv[162]	_	_
20-16	3179-3183	cSCC	event[162]|object[163]	giv[162]|giv[163]	_	_
20-17	3184-3189	cells	event[162]|object[163]	giv[162]|giv[163]	_	_
20-18	3190-3191	.	_	_	_	_

#Text=However , the mechanisms about how HOXA9 regulate apoptosis has not been explored and remain to be elucidated .
21-1	3192-3199	However	_	_	_	_
21-2	3200-3201	,	_	_	_	_
21-3	3202-3205	the	abstract[164]	giv[164]	_	_
21-4	3206-3216	mechanisms	abstract[164]	giv[164]	_	_
21-5	3217-3222	about	abstract[164]	giv[164]	_	_
21-6	3223-3226	how	abstract[164]	giv[164]	_	_
21-7	3227-3232	HOXA9	abstract	giv	coref	22-18
21-8	3233-3241	regulate	_	_	_	_
21-9	3242-3251	apoptosis	event	giv	coref	23-9
21-10	3252-3255	has	_	_	_	_
21-11	3256-3259	not	_	_	_	_
21-12	3260-3264	been	_	_	_	_
21-13	3265-3273	explored	_	_	_	_
21-14	3274-3277	and	_	_	_	_
21-15	3278-3284	remain	_	_	_	_
21-16	3285-3287	to	_	_	_	_
21-17	3288-3290	be	_	_	_	_
21-18	3291-3301	elucidated	_	_	_	_
21-19	3302-3303	.	_	_	_	_

#Text=In this study , we found RELA ( p65 subunit of NF-κB ) is transcriptionally repressed by HOXA9 .
22-1	3304-3306	In	_	_	_	_
22-2	3307-3311	this	abstract[167]	giv[167]	coref	24-1[187_167]
22-3	3312-3317	study	abstract[167]	giv[167]	_	_
22-4	3318-3319	,	_	_	_	_
22-5	3320-3322	we	person	giv	ana	24-1
22-6	3323-3328	found	_	_	_	_
22-7	3329-3333	RELA	abstract	new	coref	23-4
22-8	3334-3335	(	_	_	_	_
22-9	3336-3339	p65	abstract|quantity[171]	new|new[171]	_	_
22-10	3340-3347	subunit	quantity[171]	new[171]	_	_
22-11	3348-3350	of	quantity[171]	new[171]	_	_
22-12	3351-3356	NF-κB	quantity[171]|abstract	new[171]|new	_	_
22-13	3357-3358	)	_	_	_	_
22-14	3359-3361	is	_	_	_	_
22-15	3362-3379	transcriptionally	_	_	_	_
22-16	3380-3389	repressed	_	_	_	_
22-17	3390-3392	by	_	_	_	_
22-18	3393-3398	HOXA9	abstract	giv	_	_
22-19	3399-3400	.	_	_	_	_

#Text=In cSCC , RELA transactivates BCL-XL to antagonize apoptosis and ATG genes ( ULK1 , ATG3 , and ATG12 ) to promote autophagy .
23-1	3401-3403	In	_	_	_	_
23-2	3404-3408	cSCC	place	giv	coref	24-18
23-3	3409-3410	,	_	_	_	_
23-4	3411-3415	RELA	abstract	giv	_	_
23-5	3416-3430	transactivates	_	_	_	_
23-6	3431-3437	BCL-XL	object	giv	_	_
23-7	3438-3440	to	_	_	_	_
23-8	3441-3451	antagonize	_	_	_	_
23-9	3452-3461	apoptosis	event|abstract[178]	giv|new[178]	coref|coref	24-8[190_0]|24-8[191_178]
23-10	3462-3465	and	abstract[178]	new[178]	_	_
23-11	3466-3469	ATG	abstract[178]|abstract|abstract[180]	new[178]|giv|giv[180]	appos	23-14[182_180]
23-12	3470-3475	genes	abstract[178]|abstract[180]	new[178]|giv[180]	_	_
23-13	3476-3477	(	_	_	_	_
23-14	3478-3482	ULK1	place|abstract[182]	giv|giv[182]	_	_
23-15	3483-3484	,	abstract[182]	giv[182]	_	_
23-16	3485-3489	ATG3	abstract[182]|abstract	giv[182]|giv	_	_
23-17	3490-3491	,	abstract[182]	giv[182]	_	_
23-18	3492-3495	and	abstract[182]	giv[182]	_	_
23-19	3496-3501	ATG12	abstract[182]|abstract	giv[182]|giv	_	_
23-20	3502-3503	)	_	_	_	_
23-21	3504-3506	to	_	_	_	_
23-22	3507-3514	promote	_	_	_	_
23-23	3515-3524	autophagy	abstract	giv	coref	24-12
23-24	3525-3526	.	_	_	_	_

#Text=Our study highlights a HOXA9-NF-κB axis regulates both the apoptosis and autophagy to promote tumor development in cSCC , which may suggest novel intervention targets for cSCC therapy .
24-1	3527-3530	Our	person|abstract[187]	giv|giv[187]	_	_
24-2	3531-3536	study	abstract[187]	giv[187]	_	_
24-3	3537-3547	highlights	_	_	_	_
24-4	3548-3549	a	abstract[189]	new[189]	_	_
24-5	3550-3561	HOXA9-NF-κB	object|abstract[189]	new|new[189]	_	_
24-6	3562-3566	axis	abstract[189]	new[189]	_	_
24-7	3567-3576	regulates	_	_	_	_
24-8	3577-3581	both	event[190]|abstract[191]	giv[190]|giv[191]	_	_
24-9	3582-3585	the	event[190]|abstract[191]	giv[190]|giv[191]	_	_
24-10	3586-3595	apoptosis	event[190]|abstract[191]	giv[190]|giv[191]	_	_
24-11	3596-3599	and	abstract[191]	giv[191]	_	_
24-12	3600-3609	autophagy	abstract[191]|event	giv[191]|giv	_	_
24-13	3610-3612	to	_	_	_	_
24-14	3613-3620	promote	_	_	_	_
24-15	3621-3626	tumor	abstract|event[194]	giv|new[194]	_	_
24-16	3627-3638	development	event[194]	new[194]	_	_
24-17	3639-3641	in	event[194]	new[194]	_	_
24-18	3642-3646	cSCC	event[194]|organization	new[194]|giv	coref	24-27
24-19	3647-3648	,	_	_	_	_
24-20	3649-3654	which	_	_	_	_
24-21	3655-3658	may	_	_	_	_
24-22	3659-3666	suggest	_	_	_	_
24-23	3667-3672	novel	abstract[197]	new[197]	_	_
24-24	3673-3685	intervention	event|abstract[197]	new|new[197]	_	_
24-25	3686-3693	targets	abstract[197]	new[197]	_	_
24-26	3694-3697	for	abstract[197]	new[197]	_	_
24-27	3698-3702	cSCC	abstract[197]|abstract|abstract[199]	new[197]|giv|new[199]	_	_
24-28	3703-3710	therapy	abstract[197]|abstract[199]	new[197]|new[199]	_	_
24-29	3711-3712	.	_	_	_	_
